3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
3
Status
Unknown
1
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
4
Sponsor
Cancer Type
Gynecologic
8
Gastrointestinal
8
Genitourinary
7
Thoracic
6
Head & Neck
4
Endocrine
2
Breast
2
Sarcoma
1
NET
1
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoid Tumor
1
Interventions
Cisplatin
315
Radiotherapy
139
Cetuximab
133
pembrolizumab
131
Docetaxel
122
Carboplatin
119
Radiotherapy, Intensity-Modulated
97
Fluorouracil
94
Paclitaxel
92
Nivolumab
64
Gemcitabine
50
toripalimab
46
Radiation
44
Drug Therapy
39
Capecitabine
39
Magnetic Resonance Spectroscopy
38
Surgical Procedures, Operative
33
camrelizumab
31
130-nm albumin-bound paclitaxel
29
apatinib
27
tislelizumab
26
Chemoradiotherapy
26
Specimen Handling
25
Bevacizumab
24
durvalumab
23
Albumin-Bound Paclitaxel
23
nimotuzumab
22
lenvatinib
21
Sorafenib
21
Platinum
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 2
×
zimberelimab
×
Head & Neck
×
Clear all
NCT06727565
2026-03-02
VELOCITY-HNSCC
Gilead Sciences
Phase 2
Active not recruiting
100 enrolled
NCT04854499
2025-11-19
ELEVATE HNSCC
Gilead Sciences
Phase 2
Terminated
193 enrolled
27 charts
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled
NCT06107114
2023-11-22
CZCNRHNSCC
Sun Yat-sen University
Phase 2
Unknown
52 enrolled